Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design

Journal of Infectious Diseases

Volumn 190, Issue 5, 2004, Pages 1010-1018

  Singh, Subhash ^a   Soe, Soe ^a   Mejia, Juan Pedro ^a   Roussilhon, Christian ^a   Theisen, Michael ^b   Corradin, Giampietro ^c   Druilhe, Pierre ^a  

^a INSTITUT PASTEUR   (France)

^b STATENS SERUM INSTITUT   (Denmark)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; EPITOPE; IMMUNOGLOBULIN G; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 3; MEROZOITE SURFACE PROTEIN 3A [167-191]; MEROZOITE SURFACE PROTEIN 3B [184-210]; MEROZOITE SURFACE PROTEIN 3C [203-230]; MEROZOITE SURFACE PROTEIN 3D [211-252]; MEROZOITE SURFACE PROTEIN 3E [275-307]; MEROZOITE SURFACE PROTEIN 3F [302-354]; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CHILD; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; MALARIA; MALE; MOUSE; NONHUMAN; PARASITE; PARASITE DEVELOPMENT; PARASITOSIS; PEPTIDE SYNTHESIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN DOMAIN; STATISTICAL ANALYSIS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; DRUG DESIGN; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNOCOMPROMISED HOST; MALARIA, FALCIPARUM; MALE; MICE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS;

EID: 4344561703     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/423208     Document Type: Article

References (35)

1. Baird JK, Jones TR, Danudirgo EW, et al. Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am J Trop Med Hyg 1991; 45:65-76.
2. McGregor IA, Wilson RJM. Specific immunity: acquired in man. In: Wernsdorfer WH, McGregor IA, eds. Malaria: principles and practice of malariology. London: Churchill Livingstone, 1989:559-619.
3. Sergent E, Parrot L. L'immunité, la prémunition et la résistance innée. Arch Inst Pasteur Alger 1935; 23:279-319.
4. Cohen S, McGregor IA, Carrington S. Gamma globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.
5. Edozien JC, Gilles HM, Udeozo IO. Adult and cord-blood gamma globulin and immunity to malaria in Nigerians. Lancet 1962; 2:951-5.
6. Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991; 45:297-308.
7. Bouharoun-Tayoun H, Attanath P, Chongsuphajaisiddhi T, Druilhe P. Antibodies which protect man against P. falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro but act in cooperation with monocytes. J Exp Med 1990; 172:1633-41.
8. Bouharoun-Tayoun H, Druilhe P. Evidence for an isotype imbalance, which may be responsible for the delayed acquisition of protective immunity. Infect Immun 1992; 60:1473-81.
9. Bouharoun-Tayoun H, Druilhe P. Antibodies in falciparum malaria: what matters most, quantity or quality? Mem Inst Oswaldo Cruz 1992; 87:229-34.
10. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falaparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 2000; 68:2617-20.
11. Groux H, Gysin J. Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: functional role of IgG subclasses. Res Immunol 1990; 141:529-42.
12. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by co-operation with blood monocytes. Blood 1994; 84:1594-602.
13. Mills KE, Pearce JA, Crabb BS, Cowman AF. Truncation of merozoite surface protein-3 disrupts its trafficking and that of acidic-basic repeat protein to the surface of P. falciparum merozoites. Mol Microbiol 2002; 43:1401-11.
14. McColl DJ, Anders RF. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol 1997; 90:21-31.
15. Huber W, Felger I, Matile H, Lipps HJ, Steiger S, Beck H. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol Biochem Parasitol 1997; 87:231-4.
16. Badell E, Oeuvray C, Moreno A, et al, Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J Exp Med 2000; 192:1653-60.
17. Moreno A, Badell E, van Rooijen N, Druilhe P. Human malaria in immunocompromised mice: new in vivo model for chemotherapy studies. Antimicrob Agents Chemother 2001; 45:1847-53.
18. Theisen M, Vuust J, Gottschau A, Jespen S, Hogh B. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol 1995; 2:30-4.
19. Mattei D, Berzins K, Wahlgren M, et al, Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens. Parasite Immunol 1989;11:15-29.
20. Roggero MA, Servis C, Corradin G. A simple and rapid procedure for the purification of synthetic polypeptides by a combination of affinity chromatography and methionine chemistry. FEBS Lett 1997; 408:285-8.
21. Trape JF, Rogier C, Konate L, et al. The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg 1994; 51:123-37.
22. Behr C, Sarthou JL, Rogier C, et al. Antibodies and reactive T cells against the malaria heat-shock protein Pf72/Hsp70-1 and derived peptides in individuals continuously exposed to Plasmodium falciparum. J Immunol 1992; 149:3321-30.
23. Bottius E, BenMohamed L, Brahimi K, et al. A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. J Immunol 1996; 156:2874-84.
24. Brahimi K, Perignon JL, Bossus M, Gras H, Tartar A, Druilhe P. Fast immunopurification of small amounts of specific antibodies on peptides bound to ELISA plates. J Immunol Methods 1993; 162:69-75.
25. Druilhe P, Khusmith S. Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status. Infect Immun 1987; 55:888-91.
26. Cavanagh DR, Dobano C, Elhassan IM, et al. Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun 2001; 69:1207-11.
27. Stavnezer J. Antibody class switching. Adv Immunol 1996; 61:79-146.
28. Garraud O, Perraut R, Diouf A, et al. Regulation of antigen-specific immunoglobulin G subclasses in response to conserved and polymorphic Plasmodium falciparum antigens in an in vitro model. Infect Immun 2002; 70:2820-7.
29. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 2004; 72:247-52.
30. Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun 1995; 63:4382-8.
31. Rzepczyk CM, Hale K, Woodroffe N, et al. Humoral immune responses of Solomon Islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin G3 subclass. Infect Immun 1997; 65:1098-100.
32. Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 1998; 58:406-13.
33. Polley SD, Tetteh KK, Cavanagh DR, et al. Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria. Infect Immun 2003; 71:1833-42.
34. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 1999; 21:133-9.
35. Hisaeda H, Saul A, Reece JJ, et al. Merozoite surface protein-3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis 2002; 185:657-64.